| abstract |
The present invention provides a combination of an epigenetic factor for treating myeloid leukemia and a bispecific compound targeting CD33 and CD3, wherein the epigenetic factor is selected from histone deacetylase (HDAC). Inhibitor, DNA methyltransferase (DNMT) I inhibitor, hydroxyurea, Granulocyte-Colony Stimulating Factor (G-CSF), histone demethylase inhibition And a group of all Trans-retinoic acid (ATRA). Accordingly, the present invention provides a pharmaceutical composition comprising a CD33 targeting compound and at least one epigenetic factor, and an epigenetic factor for ameliorating and/or treating myeloid leukemia, wherein the epigenetic factor increases the patient's The reactivity of CD33 targeting compounds. Furthermore, the invention provides for the use of at least one epigenetic factor to increase the responsiveness of a myeloid leukemia patient to treatment with a CD33 targeting compound; a method for treating myeloid leukemia, the method comprising administering at least one epigenetic factornAnd a CD33 targeting compound to a patient in need thereof; and a kit comprising the pharmaceutical composition of the invention or the epigenetic factor of the invention and the bispecific CD33 targeting compound. |